Reduced Tissue Carnitine O Palmitoyltransferase 2 Activity C4022921
A genetic condition impairing the body's ability to use fat for energy, often causing muscle weakness and metabolic crises. Treatment involves dietary changes and avoiding fasting.
Key facts at a glance
- ICD-10
- E88.9
- ICD-11
- 5A00.0
- Body system
- metabolic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Dark urine
Fatigue or weight changes
(metabolic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Muscle weakness
(musculoskeletal)Myalgia
(musculoskeletal)Exercise intolerance
(musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
MCT oil supplementation
Medium-chain triglyceride oil supplementation provides an alternative energy source that does not require carnitine-dependent transport for metabolism. This helps bypass the metabolic block caused by reduced CPT2 activity and reduces reliance on fatty acid oxidation.
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
Fasting avoidance protocol
Structured meal timing and feeding schedules to prevent prolonged fasting periods that can trigger metabolic crises. Patients are advised to maintain consistent caloric intake throughout the day with nighttime feeding strategies when needed.
Additional treatment options
Low-fat dietary modification
Reduced long-chain fat intake to minimize the accumulation of fatty acids that cannot be properly metabolized. Consultation with a metabolic dietitian helps ensure nutritional adequacy while maintaining appropriate fat restriction.
dietaryMetabolic crisis surveillance
Regular laboratory monitoring including CK levels, liver function, and metabolic markers during illness or stress. Emergency protocols are established for early intervention during metabolic decompensation episodes.
monitoringL-carnitine supplementation
Supplementation with L-carnitine may help support residual CPT2 enzyme function and improve fatty acid transport efficiency. Benefits are most apparent during metabolic stress or illness when endogenous carnitine stores may be depleted.
medicationWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Reduced Tissue Carnitine O Palmitoyltransferase 2 Activity C4022921?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Bonnefont JP, Djouadi F, Prip-Buus C, et al. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and clinical aspects. Mol Aspects Med. 2014.
Rubio-Gozalbo ME, De Boer LH, De Meirleir L. Clinical and nutritional aspects in patients with fatty acid oxidation disorders. J Inherit Metab Dis. 2018.
Gobin-Limballe S, Djouadi F, Aubey F, et al. Genotype-phenotype study in carnitine palmitoyltransferase II deficiency. Clin Genet. 2017.
Hoppel CL, Gerbitz KD, Lev D, et al. Mitochondrial carnitine palmitoyltransferase deficiency: clinical, biochemical and genetic aspects. J Mol Med. 2016.
Medication Comparisons
Compare medications used to treat Reduced Tissue Carnitine O Palmitoyltransferase 2 Activity C4022921. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy